Skip to main content
    J

    Journey Medical Corp (DERM)

    Official site

    HEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NASDAQ

    $3.70
    -0.63 (-14.55%)

    Market Cap: $122.24M

    Last updated: Nov 17, 2026 at 11:04 AM ET

    Journey Medical Corp (DERM) Earnings: Report Dates and Results

    Updated Nov 12, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    In the quarter ended Sep 30, 2026, Journey Medical reported EPS of -$0.05, below the -$0.03 estimate. It beat the EPS estimate in 3 of the last 8 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    41%(14/34)
    Avg Surprise
    -4.29%

    Upcoming Estimates

    Report date not yet scheduledPeriod ending Dec 31, 2026
    EPS Consensus$0.00
    Range-$0.12 - $0.08
    6 analysts
    Revenue Consensus
    $22.02M
    Range$18.82M - $27.52M
    6 analysts

    Next Report

    DERM's report for the quarter ending Dec 31, 2026 is not on the earnings calendar yet.

    DERM Earnings Call

    The latest DERM earnings call transcript on file is labeled 2026Q3.

    Read the 2026Q3 transcript

    Earnings History

    Of the 40 quarters below that had an estimate, DERM beat 16, missed 21 and matched 3. Revenue for the quarter ended Sep 30, 2026 was $18.97M, up 7.6% from $17.63M a year earlier.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026-$0.05-$0.03-$0.08 - $0.03-66.67%MissN/A40 up, 2 downNov 12, 2026$18.97M
    Jun 30, 2026-$0.01-$0.01-$0.07 - $0.060.00%In lineN/A41 up, 1 downAug 12, 2026$18.51M
    Mar 31, 2026-$0.08-$0.09-$0.11 - -$0.05+11.11%BeatN/A40 up, 1 downMay 13, 2026$15.96M
    Dec 31, 2025-$0.04-$0.04-$0.10 - -$0.010.00%In line-140.0%40 up, 1 downMar 25, 2026$16.08M
    Sep 30, 2025-$0.09-$0.04-$0.08 - $0.01-125.00%MissN/A40 up, 1 downNov 12, 2025$17.63M
    Jun 30, 2025-$0.16-$0.10N/A-60.00%MissN/AN/A0 up, 0 downAug 12, 2025$15.01M
    Mar 31, 2025-$0.18-$0.24N/A+25.00%BeatN/AN/A0 up, 0 downMay 14, 2025$13.14M
    Dec 31, 2024$0.10-$0.17N/A+157.97%BeatN/AN/A0 up, 0 downMar 26, 2025$13.62M
    Sep 30, 2024-$0.12-$0.15-$0.21 - -$0.07+20.00%Beat-115.0%41 up, 0 downNov 12, 2024$14.63M
    Jun 30, 2024-$0.17-$0.14-$0.17 - -$0.12-21.43%MissN/A30 up, 0 downAug 12, 2024$14.86M
    Mar 31, 2024-$0.53-$0.23-$0.26 - -$0.21-130.43%MissN/A20 up, 0 downMay 13, 2024$13.03M
    Dec 31, 2023-$0.12-$0.08-$0.09 - -$0.06-50.00%MissN/A30 up, 0 downMar 21, 2024$15.26M
    Sep 30, 2023$0.80-$0.15-$0.24 - -$0.07+633.33%BeatN/A20 up, 0 downNov 7, 2023$34.54M
    Jun 30, 2023-$0.46-$0.33-$0.36 - -$0.31-39.39%MissN/A20 up, 0 downAug 8, 2023$17.17M
    Mar 31, 2023-$0.57-$0.45-$0.46 - -$0.42-26.67%MissN/A30 up, 0 downMay 22, 2023$12.21M
    Dec 31, 2022-$0.60-$0.47-$0.55 - -$0.37-27.66%MissN/A30 up, 0 downMar 29, 2023$15.97M
    Sep 30, 2022-$0.57-$0.40-$0.51 - -$0.20-42.50%MissN/A30 up, 0 downNov 10, 2022$16.12M
    Jun 30, 2022-$0.43-$0.26-$0.28 - -$0.24-65.38%MissN/A31 up, 0 downAug 9, 2022$18.29M
    Mar 31, 2022-$0.08-$0.31-$0.44 - -$0.18+74.19%BeatN/A20 up, 0 downMay 10, 2022$23.30M
    Dec 31, 2021-$1.64-$0.41-$0.66 - -$0.28-300.00%MissN/A30 up, 0 downMar 23, 2022$17.52M
    Sep 30, 2021-$1.16-$0.87N/A-33.33%MissN/AN/AN/ANov 12, 2021$19.61M
    Jun 30, 2021-$0.72-$1.30N/A+44.62%BeatN/AN/AN/ASep 1, 2021$15.29M
    Sep 30, 2019-$1.06-$1.30N/A+18.46%BeatN/AN/AN/ANov 5, 2019$11.53M
    Jun 30, 2019-$0.33-$0.95N/A+65.26%BeatN/AN/AN/AAug 7, 2019$66.64M
    Mar 31, 2019-$1.49-$1.62N/A+8.02%BeatN/AN/AN/AMay 7, 2019$2.45M
    Dec 31, 2018-$1.70-$1.91N/A+10.99%BeatN/AN/AN/AFeb 26, 2019$2.24M
    Sep 30, 2018-$1.58-$1.63N/A+3.07%BeatN/AN/AN/ANov 7, 2018$717000
    Jun 30, 2018-$0.57-$0.51N/A-11.76%MissN/AN/AN/AAug 6, 2018$39.08M
    Mar 31, 2018-$1.42-$1.36N/A-4.41%MissN/AN/AN/AMay 3, 2018$299000
    Dec 31, 2017-$1.34-$1.22N/A-9.84%MissN/AN/AN/AFeb 22, 2018$1.34M
    Sep 30, 2017-$4.30-$1.12N/A-283.93%MissN/AN/AN/ANov 6, 2017$1.07M
    Jun 30, 2017-$0.93-$0.89N/A-4.49%MissN/AN/AN/AAug 7, 2017$1.07M
    Mar 31, 2017-$0.79-$0.89N/A+11.24%BeatN/AN/AN/AMay 8, 2017$1.07M
    Dec 31, 2016-$0.21-$0.80N/A+73.75%BeatN/AN/AN/AFeb 28, 2017$22.47M
    Sep 30, 2016-$0.72-$0.72N/A0.00%In lineN/AN/AN/ANov 7, 2016$119000
    Jun 30, 2016-$0.89-$0.86N/A-3.49%MissN/AN/AN/AAug 8, 2016N/A
    Mar 31, 2016-$0.95-$0.94N/A-1.06%MissN/AN/AN/AMay 10, 2016N/A
    Dec 31, 2015-$1.04-$0.95N/A-9.47%MissN/AN/AN/AMar 3, 2016$7.30M
    Sep 30, 2015-$0.58-$0.77N/A+24.68%BeatN/AN/AN/ANov 10, 2015$7.30M
    Jun 30, 2015-$0.69-$0.75N/A+8.00%BeatN/AN/AN/AAug 13, 2015N/A
    Last 40 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was -$0.47, after -$0.72 the year before. It was -$8.96 for the year ended Dec 31, 2014, the oldest of the 10 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025-$0.47N/A
    Dec 31, 2024-$0.72N/A
    Dec 31, 2023-$0.35N/A
    Dec 31, 2022-$1.68N/A
    Dec 31, 2021-$6.40N/A
    Dec 31, 2018-$5.27N/A
    Dec 31, 2017-$7.36N/A
    Dec 31, 2016-$2.77N/A
    Dec 31, 2015-$2.88N/A
    Dec 31, 2014-$8.96N/A

    Earnings Calls

    The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 4,500 words across 9 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q3Sep 30, 20264,5159
    2026Q2Jun 30, 20264,4569
    2026Q1Mar 31, 20265,0509
    2025Q4Dec 31, 20255,2749
    2025Q3Sep 30, 20255,2609
    2025Q2Jun 30, 20253,4158
    2025Q1Mar 31, 20254,0579
    2024Q2Jun 30, 20243,6348

    2026Q3 Earnings Call

    Opening remarks

    Jaclyn Jaffe Senior Director of Corporate Operations Good afternoon, and thank you for participating in today's conference call. Joining me from Journey Medical's leadership team are Claude Maraoui, Co-Founder, President and Chief Executive Officer; Joseph Benesch, Chief Financial Officer; and Ramsey Alloush, Chief Operating Officer and General Counsel, who will participate in the Q&A portion of the call. During this call, management will be making forward-looking statements, including statements that address among other things, Journey Medical's expectations for future performance, operational results, financial condition and the receipt of regulatory approvals. Forward-looking statements involve risks and other factors that may cause actual results to differ materially from those statements. For more information about these risks, please refer to the risk factors described in Journey Medical's most recently filed periodic reports on Form 10-K and Form 10-Q, the Form 8-K filed with the SEC today and the company's press release that accompanies this call, particularly the cautionary statements in it. Today's conference call includes non-GAAP financial measures that Journey Medical believes can be useful in evaluating its performance. You should not consider this additional information in isolation or as a substitute for results prepared in accordance with GAAP. For a reconciliation of this non-GAAP financial measure to net loss, its most directly comparable GAAP financial measure, please see the reconciliation table located in the company's earnings press release. The content of this call contains time-sensitive information that is accurate only as of today, Thursday, November 12, 2026. Except as required by law, Journey Medical disclaims any obligation to publicly update or revise any information to reflect events or circumstances that occur after this call. It is now my pleasure to turn the call over to Claude Maraoui, Co-Founder, President and Chief Executive Officer of Journey Medical.

    Claude Maraoui Co-Founder, President and CEO Thank you, Jaclyn. And good afternoon to everyone on the call today. We continued to make progress in the third quarter, delivering top-line growth and improved profitability during the period. Our total revenue grew by 8% in Q3, with net product sales increasing 11% year-over-year. Net sales of Emrosi were $9 million in the third quarter, up year-over-year and sequentially from the second quarter, driven by higher prescription volume, improving payer reimbursement and an increase in the number of dermatology writers prescribing the brand. We expect that these key metrics will continue to trend positively in the coming quarters. I am pleased to report that we achieved positive EBITDA for the second consecutive quarter. We remain focused on investing in our proven dermatology commercial infrastructure and driving top-line growth to advance the business toward becoming net earnings and cash flow positive. Emrosi prescriptions totaled approximately 40,000 in the third quarter, up from about 36,000 total prescriptions in the second quarter of this year.

    Frequently Asked Questions About DERM

    Did DERM beat earnings estimates last quarter?

    No. Journey Medical reported EPS of -$0.05 for the quarter ended Sep 30, 2026, below the -$0.03 estimate by 66.67%.

    What EPS do analysts expect from DERM next quarter?

    The consensus EPS estimate for Journey Medical for the quarter ending Dec 31, 2026 is $0.00 from 6 analysts, with estimates from -$0.12 to $0.08.

    How often does DERM beat earnings estimates?

    Journey Medical beat the EPS estimate in 3 of the last 8 quarters, with an average surprise of -7.20%.